Company Overview and News

1
Want to plan your finances? Why clueless friends may have good results

22h marketwatch - 1
A new study suggests two people who don’t have a lot of money-management experience can still make sound financial decisions
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

 
China's Macro Trends Remain Compelling

2018-09-03 seekingalpha
Economic uncertainty amid trade war tensions may have some investors questioning the viability of investment in China. However, several macro trends make the Chinese economy more resilient than what headlines may suggest, even if the tit-for-tat trade conflict with the U.S. proves to be an extended affair.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

 
Introducing The Adaptive U.S. Factor ETF (AUSF)

2018-08-29 seekingalpha
On August 28th, the Global X Adaptive U.S. Factor ETF (NYSE:AUSF) began trading on the NYSE. The fund tracks the Adaptive Wealth Strategies U.S. Factor index, which seeks to outperform traditional cap-weighted indexes by employing a dynamic multi-factor investment strategy that allocates across three factors: minimum volatility, value, and momentum. To discuss the strategy in greater detail, we interviewed Kris Carroll of Adaptive Wealth Strategies, the index provider for AUSF.
SNSR AUSF AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

2
MLP Monthly Report: August 2018

2018-08-28 seekingalpha
The August MLP Monthly Report can be found here offering insights on MLP industry news, the asset class’s performance, yields, valuations, and fundamental drivers.
KKR SNSR MLPA AND LIT ETE BFIT GXG SIL KRMA GXF CHII EV ACTX CHIE GOEX FINX WMB CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA BHI ETP LNGR COPX QQQC GURU

 
Scientific Beta Factor Report: Q2 2018

2018-08-28 seekingalpha
The Global X research team updated the Scientific Beta Factor Report for Q2 2018, analyzing the performance and characteristics of factors in the US and international markets. The full Q2 Factor Report can be read here.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI SCIU ALUM MILN CJHIQ URA LNGR DM COPX QQQC GURU

 
Global X Podcast List: Back To School Edition

2018-08-28 seekingalpha
Podcasts have become an essential part of our daily routines, providing a convenient format to consume ideas, news, and entertainment. The best podcasts seamlessly blend all three, captivating listeners for learning as much as laughs. While most or all of our school days are behind us, life-long learning doesn’t end. So in the spirit of back to school season, we polled the Global X office for the team’s favorite podcasts covering familiar school topics like economics, science, history, and many others.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

 
SuperDividend® Report: Q2 2018

2018-08-12 seekingalpha
The Global X research team has posted the SuperDividend® Report for Q2, highlighting yield comparisons, performance, historical distributions, and underlying credit ratings for the Global X SuperDividend suite. Click here to read the report.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

 
How Will Colombia's Election Affect Its Economy?

2018-08-08 seekingalpha
On June 17th, Colombians elected conservative Senator Iván Duque to the presidency, whose inauguration is today, Aug. 7th, 2018. This was the first of three major Latin American (“Latam”) presidential elections heading into the second half of 2018. Duque is set to assume office at an inflection point for Colombia and his success will be measured by his ability to grow the economy while managing the variety of challenges his country faces.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX MJNA FINX CHIX SRET BOTZ CATH GURX GURI NYTAB ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

11
Leading Companies In FinTech

2018-08-08 seekingalpha - 1
The financial services industry is experiencing a technological revolution that we believe will fundamentally disrupt legacy business models. In this piece, we highlight four companies that represent key areas of the FinTech industry targeted by the Global X FinTech ETF (NASDAQ:FINX), including:
SNSR AND LIT SQNXF BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX MYO SRET BOTZ SQ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX YRD QQQC GURU ENV

 
Global X Preferred Report: Q2 2018

2018-08-08 seekingalpha
The Global X research team has posted the Global X Preferred Report for Q2, highlighting yield comparisons, performance, historical distributions, underlying credit ratings, and other preferred equity analytics for the Global X Preferred family. Click here to read the report.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

 
Q&A On The Upcoming GICS Changes

2018-08-07 seekingalpha
A shakeup in the Global Industry Classification Standard (GICS) after market close on September 28, 2018 is set to have far-reaching implications for portfolio management. First announced at their annual review in November 2017, index providers MSCI and S&P Dow Jones will rename the Telecommunications sector ‘Communications Services.’ The refreshed sector will consist of stocks from the sectors formerly known as Telecoms, Information Technology and Consumer Discretionary.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

 
Introducing The TargetIncome Family

2018-08-01 seekingalpha
On July 31st, the Global X TargetIncome 5 ETF (OTC:TFIV) and the Global X TargetIncome Plus 2 ETF (TFLT) began trading on the CBOE. Both funds seek to achieve specific yield targets, net of fees, by allocating across 11 ETFs representing different income-paying asset classes.
DB SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

 
Introducing The TargetIncome(TM) Family

2018-08-01 seekingalpha
On July 31st, the Global X TargetIncome 5 ETF (OTC:TFIV) and the Global X TargetIncome Plus 2 ETF (TFLT) began trading on the CBOE. Both funds seek to achieve specific yield targets, net of fees, by allocating across 11 ETFs representing different income-paying asset classes.
DB SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

 
Q2 Market Update

2018-07-29 seekingalpha
The first half of 2018 had plenty of drama, without much in terms of absolute returns. It was a stark contrast to the blockbuster year we had in 2017, which is now a distant memory. There were pockets of optimism, but they were largely overshadowed by the breakout of what has the real makings of an unfortunate trade war.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR WTI COPX QQQC GURU

9
MLP Monthly Report: July 2018

2018-07-29 seekingalpha
The July MLP Monthly Report can be found here offering insights on MLP industry news, the asset class’s performance, yields, valuations, and fundamental drivers.
TGE SNSR MLPA AND LIT BFIT GXG SIL KRMA GXF DVN CHII TEP EV ACTX TEGP CHIE GOEX FINX CHIX SRET BOTZ CATH GURX ENLK BWP GURI ALUM MILN ENLC CJHIQ URA BHI LNGR COPX QQQC GURU

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

11h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

13h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to SIL / Global X Funds on message board site Silicon Investor.

Silicon Investor - User Site Discussion - Generally Unmodera Silicon Investor - User Site Discussion - Generally Unmodera Silicon Investor - User Site Discussion - Generally Unmodera Gold and Silver Juniors, Mid-tiers and Producers Gold and Silver Juniors, Mid-tiers and Producers Gold and Silver Juniors, Mid-tiers and Producers
Silicon Investor - Welcome New SI Members! Silicon Investor - Welcome New SI Members! Silicon Investor - Welcome New SI Members! Silicon Motion Inc. (SIMO) Silicon Motion Inc. (SIMO) Silicon Motion Inc. (SIMO)
Kootenay Silver Kootenay Silver Kootenay Silver Silicon Investor - New feature discussion Silicon Investor - New feature discussion Silicon Investor - New feature discussion
The History of Silicon Investor The History of Silicon Investor The History of Silicon Investor Silver Bull Resources, Inc. Silver Bull Resources, Inc. Silver Bull Resources, Inc.
Clifton Mining (CFB-Alberta)-Silver Play Clifton Mining (CFB-Alberta)-Silver Play Clifton Mining (CFB-Alberta)-Silver Play Silver Recovery -- Itronics (ITRO) Silver Recovery -- Itronics (ITRO) Silver Recovery -- Itronics (ITRO)
CUSIP: 37954Y848